全球非侵入性癌症診斷市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球非侵入性癌症診斷市場預計將從2025年的837億美元成長至2034年的1,567.5億美元，2026年至2034年的複合年成長率（CAGR）為7.22%。該市場正經歷顯著成長，主要得益於人們對早期癌症檢測、個人化治療和微創診斷技術的需求不斷成長。非侵入性癌症診斷利用血液、尿液、唾液和成像技術來識別癌症生物標記物，無需進行手術切片檢查。全球癌症發生率的上升以及人們對早期診斷益處的認知不斷提高，為市場擴張創造了巨大的機會。醫療機構正擴大採用先進的診斷技術來改善患者預後並降低診斷風險。

液態生物檢體、分子診斷、基因組定序和生物標記分析等領域的技術進步是成長要素。這些技術能夠更快、更準確地檢測多種癌症類型，同時也能提高病患舒適度並降低醫療成本。癌症研究投入的增加、精準醫療計劃的擴展以及支持性的法規結構正在加速創新。人工智慧 (AI) 在診斷流程中的日益普及也提高了癌症檢測的準確性和效率。

隨著醫療系統持續重視早期診斷和個人化治療策略，前景十分光明。生物標記的發現和多癌種篩檢技術的不斷進步有望拓展臨床應用。醫療支出的成長、癌症篩檢計畫的擴大以及對非侵入性檢測解決方案需求的增加，都可能進一步推動市場成長。隨著診斷技術的普及和完善，非侵入性癌症診斷市場預計將持續成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含多個關鍵組成部分，旨在幫助您全面了解市場環境。

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的關鍵促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。本部分深入分析了競爭趨勢以及主要參與者所採取的策略，提供了寶貴的見解。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新的投資機會。本部分重點在於潛在的成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，可根據客戶需求進行調整。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更有效地支援策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球非侵入性癌症診斷市場：依產品分類

• 市場分析、洞察與預測
• 設備（病理檢測設備、聚合酵素鏈鎖反應（PCR）設備、次世代定序（NGS）設備、微陣列、影像設備（磁振造影（MRI）、電腦斷層掃描（CT）、正子斷層掃描（PET）、乳房X光攝影、其他（超音波、其他）））
• 消耗品
• 試劑盒和試劑

第5章：全球非侵入性癌症診斷市場：依技術分類

• 市場分析、洞察與預測
• 影像
• 液態切片
• 免疫檢測

第6章 全球非侵入性癌症診斷市場：依適應症分類

• 市場分析、洞察與預測
• 肺癌
• 乳癌
• 結腸癌
• 攝護腺癌
• 血癌
• 肝癌
• 子宮頸癌
• 皮膚癌
• 其他（甲狀腺癌等）

第7章 全球非侵入性癌症診斷市場：依最終用途分類

• 市場分析、洞察與預測
• 醫院
• 診斷實驗室
• 其他（學術/研究機構等）

第8章：全球非侵入性癌症診斷市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和分銷通路合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Abbott Laboratories
  • Agilent Technologies Inc
  • Canon Medical Systems Corporation
  • F. Hoffmann-La Roche Ltd
  • GE HealthCare Technologies Inc
  • Hologic Inc
  • Illumina Inc
  • Koninklijke Philips NV
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc

The global non-invasive cancer diagnostics market size is expected to reach USD 156.75 Billion in 2034 from USD 83.70 Billion in 2025, growing at a CAGR of 7.22 during 2026-2034.This market is experiencing substantial growth due to the increasing demand for early cancer detection, personalized treatment approaches, and minimally invasive diagnostic procedures. Non-invasive cancer diagnostics utilize blood samples, urine samples, saliva, and imaging technologies to identify cancer biomarkers without the need for surgical biopsies. Rising cancer prevalence worldwide and growing awareness regarding the benefits of early diagnosis are creating significant opportunities for market expansion. Healthcare providers are increasingly adopting advanced diagnostic technologies to improve patient outcomes and reduce diagnostic risks.

Technological advancements in liquid biopsy, molecular diagnostics, genomic sequencing, and biomarker analysis are major growth drivers for the market. These technologies enable faster and more accurate detection of multiple cancer types while improving patient comfort and reducing healthcare costs. Increasing investments in oncology research, expanding precision medicine initiatives, and supportive regulatory frameworks are accelerating innovation. The growing adoption of artificial intelligence in diagnostic workflows is also enhancing the accuracy and efficiency of cancer detection.

Future prospects remain highly promising as healthcare systems continue to prioritize early diagnosis and personalized treatment strategies. Ongoing advancements in biomarker discovery and multi-cancer screening technologies are expected to expand clinical applications. Rising healthcare expenditures, increasing cancer screening programs, and growing demand for non-invasive testing solutions will further support market growth. As diagnostic technologies become more accessible and sophisticated, the non-invasive cancer diagnostics market is expected to witness sustained expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Instruments (Pathology-based Instruments, Polymerase Chain Reaction (PCR) Instruments, Next-generation Sequencing (NGS) Instruments, Microarrays, Imaging Instruments (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Mammography, Others (Ultrasound, etc.)))
• Consumables
• Kits & Reagents

By Technology

• Imaging
• Liquid Biopsy
• Immunoassay

By Indication

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Blood Cancer
• Liver Cancer
• Cervical Cancer
• Skin Cancer
• Others (Thyroid Cancer, etc.)

By End Use

• Hospitals
• Diagnostic Laboratories
• Others (Academic & Research Institutes, etc.)

COMPANIES PROFILED

• Abbott Laboratories, Agilent Technologies Inc., Canon Medical Systems Corporation, F. Hoffmann-La Roche Ltd, GE HealthCare Technologies Inc., Hologic Inc., Illumina Inc., Koninklijke Philips N.V., QIAGEN N.V., Quest Diagnostics Incorporated, Siemens Healthineers AG, Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL NON-INVASIVE CANCER DIAGNOSTICS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Instruments (Pathology-based Instruments, Polymerase Chain Reaction (PCR) Instruments, Next-generation Sequencing (NGS) Instruments, Microarrays, Imaging Instruments (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Mammography, Others (Ultrasound, etc.))) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Kits & Reagents Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NON-INVASIVE CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Technology
• 5.2. Imaging Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Liquid Biopsy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Immunoassay Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NON-INVASIVE CANCER DIAGNOSTICS MARKET: BY INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Indication
• 6.2. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Blood Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Liver Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.8. Cervical Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.9. Skin Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.10. Others (Thyroid Cancer, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL NON-INVASIVE CANCER DIAGNOSTICS MARKET: BY END USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End Use
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others (Academic & Research Institutes, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL NON-INVASIVE CANCER DIAGNOSTICS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Technology
  • 8.2.3 By Indication
  • 8.2.4 By End Use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Technology
  • 8.3.3 By Indication
  • 8.3.4 By End Use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Technology
  • 8.4.3 By Indication
  • 8.4.4 By End Use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Technology
  • 8.5.3 By Indication
  • 8.5.4 By End Use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Technology
  • 8.6.3 By Indication
  • 8.6.4 By End Use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL NON-INVASIVE CANCER DIAGNOSTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Abbott Laboratories
  • 10.2.2 Agilent Technologies Inc
  • 10.2.3 Canon Medical Systems Corporation
  • 10.2.4 F. Hoffmann-La Roche Ltd
  • 10.2.5 GE HealthCare Technologies Inc
  • 10.2.6 Hologic Inc
  • 10.2.7 Illumina Inc
  • 10.2.8 Koninklijke Philips N.V
  • 10.2.9 QIAGEN N.V
  • 10.2.10 Quest Diagnostics Incorporated
  • 10.2.11 Siemens Healthineers AG
  • 10.2.12 Thermo Fisher Scientific Inc